Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BONTRIL PDM vs DAYPRO ALTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
FDA-approved: Chronic weight management (BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity) as an adjunct to a reduced-calorie diet and increased physical activity.,Off-label: None widely recognized.
Rheumatoid arthritis,Osteoarthritis,Juvenile idiopathic arthritis,Ankylosing spondylitis (off-label),Acute gout (off-label)
Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.
Oxaprozin is administered orally. The usual adult dose is 1200 mg once daily. For osteoarthritis and rheumatoid arthritis, dosing can range from 600 to 1200 mg once daily. A starting dose of 600 mg once daily may be considered for patients with low body weight or milder disease.
Terminal elimination half-life is 12-15 hours in adults, prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
50-65 hours (mean 57 hours); clinically significant accumulation occurs with multiple dosing, requiring dose adjustment in elderly and renal impairment.
Phentermine: primarily renal excretion (unchanged). Topiramate: metabolized by CYP3A4 (minor), but ~70% excreted unchanged in urine. Also undergoes hydrolysis and glucuronidation.
Primarily hepatic via cytochrome P450 (CYP) 2C9 and CYP2C8; minor metabolism via glucuronidation. Metabolites are inactive.
Renal: ~70% (unchanged), Fecal: ~30% (biliary excretion of metabolites).
Renal: 85% (60-90% as oxaprozin glucuronide and 5-10% as unchanged oxaprozin); Fecal: <5%; Biliary: negligible.
98% bound to albumin.
>99.5% bound to albumin.
0.25-0.35 L/kg, indicating distribution primarily in extracellular fluid.
0.15-0.25 L/kg; low Vd indicates extensive plasma protein binding and limited tissue distribution.
Oral: 65-75% (first-pass metabolism); IM: 85-95%.
Oral: approximately 100% (well absorbed with no significant first-pass metabolism).
GFR >30 m L/min: No adjustment. GFR 10-30 m L/min: Use with caution, reduce dose by 50%. GFR <10 m L/min: Contraindicated.
For patients with creatinine clearance (Cr Cl) of 50-79 m L/min: no dose adjustment is generally required, but monitor for adverse effects. For Cr Cl 30-49 m L/min: reduce dose by 50% or use 600 mg once daily. For Cr Cl <30 m L/min: use is contraindicated. End-stage renal disease (ESRD): avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
Child-Pugh Class A (mild impairment): no dose adjustment needed. Child-Pugh Class B (moderate impairment): reduce dose by 50% or use 600 mg once daily; monitor closely. Child-Pugh Class C (severe impairment): use is contraindicated. No specific studies; caution advised.
Children 6-12 years: 2.5-5 mg once daily; maximum 10 mg/day. Children >12 years: Same as adult dosing.
Not approved for pediatric use. Safety and efficacy have not been established in patients under 18 years. Avoid use in children and adolescents unless under expert guidance and with caution.
Initiate at 2.5 mg once daily; may increase to 5 mg if needed. Use with caution due to increased sensitivity.
Elderly patients (≥65 years) are at increased risk for NSAID-related adverse effects, including GI bleeding, renal impairment, and cardiovascular events. Initiate therapy at the lowest effective dose (e.g., 600 mg once daily) and monitor renal function, blood pressure, and for signs of GI toxicity. Avoid use if possible in patients with high cardiovascular risk or history of GI ulceration.
No black box warning for the combination product. However, topiramate is associated with an increased risk of acute myopia and secondary angle closure glaucoma, and teratogenicity (cleft lip/palate with first-trimester exposure).
Cardiovascular risk: NSAIDs may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use and in patients with cardiovascular risk factors. Gastrointestinal risk: NSAIDs increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines, which can be fatal. These events can occur at any time without warning.
Acute myopia and angle-closure glaucoma (topiramate); discontinue if symptoms occur.,Oligohidrosis and hyperthermia (topiramate), especially in pediatric use.,Fetal toxicity (topiramate): increased risk of oral clefts; contraception required for females of reproductive potential.,Suicidal behavior or ideation (topiramate).,Metabolic acidosis (topiramate): monitor serum bicarbonate.,Increase in heart rate (phentermine): use with caution in patients with cardiac disease.,Pulmonary hypertension (phentermine): rare but serious.,Dependence and abuse potential (phentermine, Schedule IV controlled substance).,Glaucoma angle closure risk.,Kidney stones (topiramate): hydrate to prevent.,Cognitive/neuropsychiatric effects (topiramate): difficulty with memory, concentration, or language.
Cardiovascular thrombotic events (MI, stroke),Gastrointestinal bleeding, ulceration, perforation,Renal toxicity (elevated creatinine, nephrotoxicity),Hepatic effects (transaminase elevations, rare severe hepatotoxicity),Hypertension exacerbation,Fluid retention and edema,Anaphylactoid reactions,Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome),Premature closure of ductus arteriosus in pregnancy,Hematologic effects (anemia, bleeding)
Glaucoma (angle-closure), especially with topiramate component.,Hyperthyroidism (phentermine).,Patients with a history of drug abuse (phentermine).,MAO inhibitor use within 14 days (phentermine).,Pregnancy (topiramate is teratogenic).,Breastfeeding (safety not established).,Known hypersensitivity to phentermine or topiramate.,Cardiovascular disease including arrhythmias, coronary artery disease, or uncontrolled hypertension (phentermine).,Concomitant use of other central nervous system stimulants.
Hypersensitivity to oxaprozin or any NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,In setting of coronary artery bypass graft (CABG) surgery,Advanced renal disease,Pregnancy (third trimester) due to risk of preterm closure of ductus arteriosus and oligohydramnios
Avoid alcohol and caffeine-containing products. High-fat meals may delay absorption. No other specific food restrictions, but follow a reduced-calorie diet as advised by your healthcare provider.
May be taken with food or milk to minimize gastrointestinal irritation. Avoid alcohol due to increased risk of GI bleeding. No specific food restrictions otherwise.
First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal hemorrhage and premature closure of ductus arteriosus.
First trimester: NSAIDs are not associated with a major teratogenic risk, but avoid due to potential risk of miscarriage. Second trimester: Use only if clearly needed. Third trimester: Avoid after 30 weeks due to premature closure of ductus arteriosus and oligohydramnios. DAYPRO ALTA (oxaprozin) is contraindicated in third trimester.
Excreted into breast milk with M/P ratio of 0.8. Contraindicated during breastfeeding due to risk of infant toxicity (renal impairment, bleeding).
Oxaprozin is excreted in human milk; M/P ratio is approximately 0.5. Due to potential adverse effects on infant, caution is advised. Use only if benefit outweighs risk, consider alternative agents.
No established safe dose due to teratogenicity. If inadvertent exposure occurs, immediate discontinuation recommended. No dose adjustment is feasible given contraindication.
In pregnancy, oxaprozin clearance may increase; however, no specific dose adjustment is recommended. Use lowest effective dose for shortest duration during first and second trimesters. Avoid in third trimester.
BONTRIL PDM (phendimetrazine tartrate) is a sympathomimetic amine anorectic. Monitor blood pressure and heart rate due to potential increases. Avoid use in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, glaucoma, or MAOI use within 14 days. Taper to avoid abrupt discontinuation. Not recommended for pediatric patients or those with hypertension.
Daypro Alta (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~40-50 hours) allowing once-daily dosing. Monitor for GI bleeding, renal impairment, and cardiovascular events. Use with caution in elderly and those with renal insufficiency. Avoid in patients with aspirin-sensitive asthma or NSAID allergy.
Take exactly as prescribed; do not exceed recommended dose.,Avoid driving or operating machinery until you know how this medication affects you.,Report chest pain, shortness of breath, or palpitations immediately.,Do not take with other stimulants or diet aids.,Inform your doctor if you become pregnant or plan to breastfeed.,Do not stop suddenly without consulting your doctor.
Take with food or milk to reduce stomach upset.,Do not take other NSAIDs or aspirin while on this medication.,Report any signs of stomach bleeding (black stools, coffee-ground vomit), chest pain, or swelling.,Avoid alcohol as it increases GI bleeding risk.,Tell your doctor about all medications, especially blood thinners and diuretics.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BONTRIL PDM vs DAYPRO ALTA, answered by our medical review team.
BONTRIL PDM is a Sympathomimetic Anorectic that works by Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.. DAYPRO ALTA is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BONTRIL PDM and DAYPRO ALTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BONTRIL PDM is: Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.. The standard adult dose of DAYPRO ALTA is: Oxaprozin is administered orally. The usual adult dose is 1200 mg once daily. For osteoarthritis and rheumatoid arthritis, dosing can range from 600 to 1200 mg once daily. A starting dose of 600 mg once daily may be considered for patients with low body weight or milder disease.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BONTRIL PDM and DAYPRO ALTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BONTRIL PDM is classified as Category C. First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal . DAYPRO ALTA is classified as Category C. First trimester: NSAIDs are not associated with a major teratogenic risk, but avoid due to potential risk of miscarriage. Second trimester: Use only if clearly needed. Third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.